Given that ketamine, another FDA-approved NMDAR antagonist, is currently widely used to treat status epilepticus (Ilvento et al., 2015; Zeiler, 2015; Pribish et al., 2020), and has been used to treat refractory epilepsy in patient with a GRIN2D mutation (Li et al., 2016), we evaluated its neuroprotective profile in GluN2A-P552R mediated neurotoxicity. The gene discussed is GRIN2A; the disease is status epilepticus.